AKT2 and AKT3 Knockout A-549 Cell Line

AKT (Protein Kinase B) is a family of three paralogous serine/threonine kinases (AKT1/PKBα, AKT2/PKBβ, AKT3/PKBγ) that are activated downstream of PI3K signaling — PI3K generates PIP3, which recruits AKT to the plasma membrane via its PH domain; AKT is then phosphorylated at T308 (activation loop, by PDK1) and S473 (hydrophobic motif, by mTORC2) for full activation. AKT family members share substantial substrate scope but have distinct tissue expression and functions: AKT1 is broadly expressed and important in cell survival/growth; AKT2 is enriched in insulin-sensitive tissues (liver, muscle, adipose) and central to insulin signaling; AKT3 is enriched in brain and testis with roles in neural development. Substantial paralog redundancy means that single-isoform knockouts often show modest phenotypes — paired and combination knockouts are essential for systematic functional dissection. This AKT2 & AKT3 Double Knockout in A-549 is uniquely valuable for asking which functions are AKT1-dependent versus AKT2/AKT3-dependent — combined loss of AKT2 and AKT3 leaves only AKT1 as the functional AKT isoform. Single-isoform rescue (AKT2 alone or AKT3 alone) in the double knockout enables paralog-specific functional dissection — this is the gold-standard experimental design for AKT paralog studies. For systematic AKT family research, the EDITGENE AKT2 & AKT3 Double Knockout in A-549 is part of a complete EDITGENE AKT paralog dissection toolkit (single AKT1, single AKT2, double AKT1&AKT2, double AKT1&AKT3, double AKT2&AKT3 — all in A-549 NSCLC background). This systematic matrix enables comprehensive AKT family functional analysis. The knockout is a critical specificity tool for ⭐⭐ capivasertib (Truqap, FDA-approved 2023 pan-AKT inhibitor for HR+/HER2− breast cancer with PIK3CA/AKT1/PTEN alterations), ipatasertib, MK-2206 (allosteric AKT inhibitor), ARQ-092/miransertib, and isoform-selective emerging AKT inhibitors.

Primary applications: • AKT1-only signaling: pure AKT1-mediated PI3K signaling analysis given AKT2/3 loss. • Pan-AKT inhibitor specificity: critical genetic control for ⭐⭐ capivasertib (Truqap), ipatasertib, MK-2206 — these compounds should show retained activity through AKT1 in this double KO. • Single-isoform rescue: AKT2 alone or AKT3 alone re-introduction enables paralog-specific dissection — gold-standard experimental design. • AKT paralog matrix dissection: combined analysis with all five AKT KOs in A-549 (single AKT1, single AKT2, double AKT1&2, double AKT1&3, double AKT2&3 — all available). EDITGENE recommends this double KO as part of the systematic AKT paralog dissection toolkit for capivasertib-class cancer drug development.

Yes, and rescue experiments are uniquely powerful in this AKT2&3 double knockout: • Single-isoform rescue: ⭐ re-introduction of AKT2 alone or AKT3 alone enables paralog-specific dissection — gold-standard experimental design. • Construct design: use codon-modified AKT2 or AKT3 sequences with small C-terminal tags (FLAG, HA) — preserve PH domain, kinase domain, and regulatory C-terminus. • Kinase-dead rescue: K181M (AKT2) or K177M (AKT3) ATP-binding lysine mutations abolish catalytic activity. • Constitutively active rescue: myristoylated AKT (myr-AKT) constitutive plasma membrane localization generates active AKT without PI3K input. • Functional readout: rescue should restore PI3K-AKT signaling measured by phospho-substrates (GSK3β S9, FOXO1 T24, S6K T389). A-549-specific considerations: • A-549 is a human non-small cell lung carcinoma (NSCLC) cell line widely used for lung cancer drug development. • Lentiviral transduction is supported with moderate efficiency. • A-549's PI3K-AKT pathway activity makes it a relevant context for systematic AKT paralog research.